Kendra A Young1, Matthew Strand2, Margaret F Ragland3, Gregory L Kinney1, Erin E Austin4, Elizabeth A Regan5, Katherine E Lowe1, Barry J Make5, Edwin K Silverman6, James D Crapo5, John E Hokanson1. 1. Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora. 2. Division of Biostatistics and Bioinformatics, Office of Academic Affairs, National Jewish Health, Denver, Colorado. 3. Department of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora. 4. Department of Mathematical and Statistical Sciences, University of Colorado at Denver. 5. Department of Medicine, National Jewish Health, Denver, Colorado. 6. Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Abstract
RATIONALE: We classified individuals into pulmonary disease subtypes based on 2 underlying pathophysiologic disease axes (airway-predominant and emphysema-predominant) and their increased mortality risk. Our next objective was to determine whether some subcomponents of these subtypes are additionally associated with unique patterns of Global initiative for chronic Obstructive Lung Disease (GOLD) spirometry stage progression. METHODS: After accounting for intra-individual measurement variability in spirometry measures between baseline (Phase 1) and the 5-year follow up (Phase 2) of the COPD Genetic Epidemiology (COPDGene®) study, 4615 individuals had complete data that would characterize patterns of disease progression over 5 years (2033 non-Hispanic whites; 827 African Americans; 48% female). Individuals could express increased risk for mortality on one or both of the primary subtype axes (airway-predominant or emphysema-predominant) and thus they were further classified into 6 groups: high-risk airway-predominant disease only (APD-only), moderate-risk airway-predominant disease only (MR-APD-only), high-risk emphysema-predominant disease only (EPD-only), combined high-risk airway- and emphysema-predominant disease (combined APD-EPD), combined moderate-risk airway- and emphysema-predominant disease (combined MR-APD-EPD), and no high-risk pulmonary subtype. Outcomes were dichotomized for GOLD spirometry stage progression from Phase 1 to Phase 2. Logistic regression of the progression outcomes on the pulmonary subtypes were adjusted for age, sex, race, and change in smoking status. RESULTS: The MR-APD-only group was associated with conversion from GOLD 0 to preserved ratio-impaired spirometry (PRISm) status (odds ratio [OR] 11.3, 95% confidence interval [CI] 5.7-22.1) and GOLD 0 to GOLD 2-4 (OR 6.0, 95% CI 2.0-18.0). The EPD-only group was associated with conversion from GOLD 0 to GOLD 1 (OR 2.4, 95% CI 1.2-4.6), and GOLD 1 to GOLD 2-4 (OR 2.6, 95% CI 1.0-6.9). Conversion between PRISm and GOLD 2-4 (31%-38%) occurred in both the APD-only and the MR-APD-only groups. CONCLUSION: Differential conversion occurs from GOLD 0 to PRISm and GOLD 0 to GOLD 1 based on groups expressing airway-predominant disease or emphysema-predominant disease independently or in combination. Airway-predominant and emphysema-predominant subtypes are highly important in determining patterns of early disease progression. JCOPDF
RATIONALE: We classified individuals into pulmonary disease subtypes based on 2 underlying pathophysiologic disease axes (airway-predominant and emphysema-predominant) and their increased mortality risk. Our next objective was to determine whether some subcomponents of these subtypes are additionally associated with unique patterns of Global initiative for chronic Obstructive Lung Disease (GOLD) spirometry stage progression. METHODS: After accounting for intra-individual measurement variability in spirometry measures between baseline (Phase 1) and the 5-year follow up (Phase 2) of the COPD Genetic Epidemiology (COPDGene®) study, 4615 individuals had complete data that would characterize patterns of disease progression over 5 years (2033 non-Hispanic whites; 827 African Americans; 48% female). Individuals could express increased risk for mortality on one or both of the primary subtype axes (airway-predominant or emphysema-predominant) and thus they were further classified into 6 groups: high-risk airway-predominant disease only (APD-only), moderate-risk airway-predominant disease only (MR-APD-only), high-risk emphysema-predominant disease only (EPD-only), combined high-risk airway- and emphysema-predominant disease (combined APD-EPD), combined moderate-risk airway- and emphysema-predominant disease (combined MR-APD-EPD), and no high-risk pulmonary subtype. Outcomes were dichotomized for GOLD spirometry stage progression from Phase 1 to Phase 2. Logistic regression of the progression outcomes on the pulmonary subtypes were adjusted for age, sex, race, and change in smoking status. RESULTS: The MR-APD-only group was associated with conversion from GOLD 0 to preserved ratio-impaired spirometry (PRISm) status (odds ratio [OR] 11.3, 95% confidence interval [CI] 5.7-22.1) and GOLD 0 to GOLD 2-4 (OR 6.0, 95% CI 2.0-18.0). The EPD-only group was associated with conversion from GOLD 0 to GOLD 1 (OR 2.4, 95% CI 1.2-4.6), and GOLD 1 to GOLD 2-4 (OR 2.6, 95% CI 1.0-6.9). Conversion between PRISm and GOLD 2-4 (31%-38%) occurred in both the APD-only and the MR-APD-only groups. CONCLUSION: Differential conversion occurs from GOLD 0 to PRISm and GOLD 0 to GOLD 1 based on groups expressing airway-predominant disease or emphysema-predominant disease independently or in combination. Airway-predominant and emphysema-predominant subtypes are highly important in determining patterns of early disease progression. JCOPDF
Authors: Shawn D Aaron; Wan C Tan; Jean Bourbeau; Don D Sin; Robyn H Loves; Jenna MacNeil; George A Whitmore Journal: Am J Respir Crit Care Med Date: 2017-08-01 Impact factor: 21.405
Authors: Anne Lindberg; A Bjerg; Anders Bjerg-Bäcklund; Eva Rönmark; Lars-Gunnar Larsson; Bo Lundbäck Journal: Respir Med Date: 2005-06-21 Impact factor: 3.415
Authors: Mehrdad Arjomandi; Siyang Zeng; Igor Barjaktarevic; R Graham Barr; Eugene R Bleecker; Russell P Bowler; Russell G Buhr; Gerard J Criner; Alejandro P Comellas; Christopher B Cooper; David J Couper; Jeffrey L Curtis; Mark T Dransfield; MeiLan K Han; Nadia N Hansel; Eric A Hoffman; Robert J Kaner; Richard E Kanner; Jerry A Krishnan; Robert Paine; Stephen P Peters; Stephen I Rennard; Prescott G Woodruff Journal: Eur Respir J Date: 2019-10-31 Impact factor: 16.671
Authors: Jeffrey I Stewart; Sarah Moyle; Gerard J Criner; Carla Wilson; Ron Tanner; Russell P Bowler; James D Crapo; Robert K Zeldin; Barry J Make; Elizabeth A Regan Journal: COPD Date: 2012-06-07 Impact factor: 2.409
Authors: Jean-Paul Charbonnier; Esther Pompe; Camille Moore; Stephen Humphries; Bram van Ginneken; Barry Make; Elizabeth Regan; James D Crapo; Eva M van Rikxoort; David A Lynch Journal: Respir Med Date: 2018-11-20 Impact factor: 3.415
Authors: Jørgen Vestbo; Lisa D Edwards; Paul D Scanlon; Julie C Yates; Alvar Agusti; Per Bakke; Peter M A Calverley; Bartolome Celli; Harvey O Coxson; Courtney Crim; David A Lomas; William MacNee; Bruce E Miller; Edwin K Silverman; Ruth Tal-Singer; Emiel Wouters; Stephen I Rennard Journal: N Engl J Med Date: 2011-09-26 Impact factor: 91.245
Authors: Emily S Wan; Peter J Castaldi; Michael H Cho; John E Hokanson; Elizabeth A Regan; Barry J Make; Terri H Beaty; MeiLan K Han; Jeffrey L Curtis; Douglas Curran-Everett; David A Lynch; Dawn L DeMeo; James D Crapo; Edwin K Silverman Journal: Respir Res Date: 2014-08-06
Authors: Katherine E Lowe; John E Hokanson; Barry J Make; Katherine A Pratte; Elizabeth A Regan; Edwin K Silverman; Kendra A Young; Gregory L Kinney; James D Crapo Journal: Chronic Obstr Pulm Dis Date: 2020-04
Authors: Emily S Wan; John E Hokanson; Elizabeth A Regan; Kendra A Young; Barry J Make; Dawn L DeMeo; Stefanie E Mason; Raul San Jose Estepar; James D Crapo; Edwin K Silverman Journal: Chest Date: 2021-09-27 Impact factor: 9.410
Authors: Fortune O Alabi; Hadaya A Alkhateeb; Kayla M DeBarros; Pierina S Barletti Benel; Rachel L Sanchez-Martez; Mia L Zeper; Reema A Ismail; Fred Umeh; Nelson Medina-Villanueva Journal: Chronic Obstr Pulm Dis Date: 2021-07-28
Authors: Mathias Schlögl; Anand S Iyer; Florian Riese; David Blum; Lanier O'Hare; Tejaswini Kulkarni; Sophie Pautex; Jan Schildmann; Keith M Swetz; Pallavi Kumar; Christopher A Jones Journal: J Palliat Med Date: 2021-07-14 Impact factor: 2.947